B4GALT1 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 5 bp deletion in exon 1.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 5 bp deletion in exon 1.
Alternative names
384.Beta-N-acetylglucosaminyl-glycolipid beta-1,4-galactosyltransferase, 4-GalTase 1, 4-galactosyltransferase 1, B4GT1_HUMAN, Beta-1, Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase, Beta4Gal-T1, CDG2D, GGTB2, GT1, GTB, Lactose synthase A protein, N-acetyllactosamine synthase, Nal synthase, Processed beta-1, UDP-Gal:beta-GlcNAc beta-1, UDP-galactose:beta-N-acetylglucosamine beta-1
What's included?
Recommended products
B4GALT1 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 5 bp deletion in exon 1.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 5 bp deletion in exon 1.
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- B4GALT1
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
B4GALT1 also known as beta-14-galactosyltransferase 1 is an enzyme that facilitates the transfer of galactose residues from UDP-galactose to acceptor sugars forming β1-4 galactosidic linkages. This enzyme has an approximate mass of 60 kDa. It is primarily expressed in the Golgi apparatus of many cell types including epithelial cells and fibroblasts. B4GALT1 represents one of seven beta-14-galactosyltransferase enzymes each with varying specificity and function depending on the tissue type.
- Biological function summary
B4GALT1 plays an important role in the modification of glycoproteins and glycolipids. It acts as part of a larger complex responsible for the formation and maintenance of glycan structures on cellular proteins which are important for cell-cell communication and protein stability. This modification process is essential for normal cellular functions because it impacts protein folding secretion and cell surface expression. B4GALT1 achieves this by participating in the synthesis of N-linked and O-linked glycans which directly influences various physiological processes.
- Pathways
B4GALT1 functions in the glycosylation pathway where it modifies oligosaccharide chains during protein post-translational modification. This pathway is essential for the synthesis of glycoproteins which play a role in cell adhesion and signaling. B4GALT1 also contributes to the protein N-glycosylation metabolic pathway and interacts with proteins like ST3GAL1 which modify glycan structures further. These pathways are indispensable for proper cellular communication and function.
- Associated diseases and disorders
Defects or dysregulation of B4GALT1 can lead to conditions such as congenital disorders of glycosylation. Mutations in this enzyme have been linked to neurological and developmental abnormalities due to impaired glycan synthesis. B4GALT1 has also shown relevance in cancer influencing tumor progression and metastasis. It interacts with MUC1 a protein that when aberrantly glycosylated can promote cancer cell invasiveness and impede immune response therefore affecting cancer prognosis.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Sanger Sequencing - Human B4GALT1 knockout HeLa cell lysate (ab258323)
Allele-2: 1 bp insertion in exon 1
Sanger Sequencing - Human B4GALT1 knockout HeLa cell lysate (ab258323)
Allele-1: 5 bp deletion in exon 1
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com